Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 21 versus TRI PREVIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 21 versus TRI PREVIFEM.
ORTHO-NOVUM 7/7/7-21 vs TRI-PREVIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
Combination oral contraceptive: ethinyl estradiol and norgestimate exert contraceptive effects primarily by suppression of gonadotropin secretion (FSH and LH), thereby inhibiting ovulation. Additionally, progestin induces changes in cervical mucus and endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo; repeat cycle.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Ethinyl estradiol: terminal half-life 13-27 hours; norgestimate: terminal half-life of norelgestromin (active metabolite) 12-30 hours; clinical context: once-daily dosing provides steady-state concentrations within 7-10 days.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Ethinyl estradiol: 40% renal, 60% fecal; norgestimate and its metabolites: 80% renal, 20% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive